Prenatal genetic screening in the Ashkenazi Jewish population

Clinics in Perinatology

Volumn 28, Issue 2, 2001, Pages 367-382

  Zinberg, Randi E ^a   Kornreich, Ruth ^a   Edelmann, Lisa ^a   Desnick, Robert J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOSOMAL RECESSIVE DISORDER; BLOOM SYNDROME; CANAVAN DISEASE; CYSTIC FIBROSIS; DYSAUTONOMIA; FANCONI ANEMIA; GAUCHER DISEASE; GENE FREQUENCY; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HUMAN; JEW; MASS SCREENING; MUCOLIPIDOSIS; NIEMANN PICK DISEASE; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; TAY SACHS DISEASE;

EID: 0034897979     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-5108(05)70089-0     Document Type: Article

References (66)

1. Mucolipidosis type IV: Clinical spectrum and natural history
2. Familial dysautonomia is caused by mutations of the IKAP gene
3. Identification of an altered splice site in Ashkenazi Tay-Sachs disease
4. Fanconi's anemia: Genetic testing in Ashkenazi Jews
5. Fanconi's anemia
6. Familial dysautonomia
7. Identification of the gene causing mucolipidosis type IV
8. Cloning of the gene encoding a novel integral membrane protein, mucolipidin, and identification of the two major founder mutations causing mucolipidosis type IV
9. Aspartoacylase deficiency
10. Gaucher's disease
11. Screening for carriers of Tay-Sachs disease in the ultraorthodox Ashkenazi Jewish community in Israel
12. Molecular diagnosis and carrier screening for beta thalassemia
13. A second mutation associated with apparent beta-hexosaminidase A pseudodeficiency: Identification and frequency estimation
14. Population-specific screening by mutation analysis for diseases frequent in Ashkenazi Jews
15. First-trimester biochemical and molecular diagnoses using chorionic villi: High accuracy in the U.S. collaborative study
16. A fully automated method for identification of Tay-Sachs disease carriers by tear beta-hexosaminidase assay
17. Gaucher's disease: The origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations
18. Prenatal genetic carrier testing using triple disease screening
19. Preimplantation genetic diagnosis principles and ethics
20. Bloom syndrome
21. First-trimester prenatal diagnosis of Tay-Sachs disease
22. Enzyme therapy for Gaucher's disease: The first 5 years
23. The GM2 gangliosidoses
24. Distribution of three alpha-chain beta-hexosaminidase A mutations among Tay-Sachs carriers
25. Perspectives in genetic screening: Principles and implications
26. Automated thermal fractionation of serum hexosaminidase: Effects of alteration in reaction variables and implications for Tay-Sachs disease heterozygote screening
27. Tay-Sachs disease carrier screening, prenatal diagnosis, and the molecular era: An international perspective, 1970 to 1993
28. Prevalence of Canavan's disease heterozygotes in the New York metropolitan Ashkenazi Jewish population
29. Prenatal genetics screening in the Ashkenazi Jewish population: A pilot program of muliple option testing for five disorders
30. Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population
31. Gaucher's's disease: A model for modern management of a genetic disease
32. Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: Evidence against a single defect within this ethnic group
33. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene
34. The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase
35. Different mutations in Ashkenazi Jewish and non-Jewish French Canadians with Tay-Sachs disease
36. Human beta-hexosaminidase alpha chain: Coding sequence and homology with the beta chain
37. cDNA clone for the alpha-chain of human beta-hexosaminidase: Deficiency of alpha-chain mRNA in Ashkenazi Tay-Sachs fibroblasts
38. Founder effect in Tay-Sachs disease unlikely
39. Adult GM2 gangliosidosis in association with Tay-Sachs disease: A new phenotype
40. The mutations in Ashkenazi Jews with adult GM2 gangliosidosis, the adult form of Tay-Sachs disease
41. Tay-sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay
42. Tay-Sachs disease: Generalized absence of a beta-D-N-acetylhexosaminidase component
43. Frequency of three Hex A mutant alleles among Jewish and non-Jewish carriers identified in a Tay-Sachs screening program
44. Gene encoding the human beta-hexosaminidase beta chain: Extensive homology of intron placement in the alpha- and beta-chain genes
45. Organization of the gene encoding the human beta-hexosaminidase alpha-chain
46. Mucolipidosis type IV: The origin of the disease in the Ashkenazi Jewish population
47. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population
48. Niemann-Pick disease types A and B: Acid sphingomyelinase deficiencies
49. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia
50. Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel
51. Detection of Tay-Sachs disease heterozygotes by assay of hexosaminidase A in serum and leukocytes
52. Distribution of a pseudodeficiency allele among Tay-Sachs carriers
53. Screening for carriers of Tay-Sachs disease among Ashkenazi Jews: A comparison of DNA-based and enzymebased tests
54. A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: Implications for carrier screening
55. Tay-Sachs disease: Compatibility screening in the Orthodox Jewish community
56. Cystic fibrosis
57. Comparison of enzyme and DNA analysis in a Tay-Sachs disease carrier screening program
58. Chorionic villi sampling for early prenatal diagnosis: An option for the Jewish orthodox community